Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs T Rowe Price Group Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while T Rowe Price Group Inc trades at $117.75 (market cap $24.87B). The key difference: T Rowe Price Group Inc is far larger — about 3.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and T Rowe Price Group Inc pays a 4.48% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | TROW | |
|---|---|---|
Market Cap | $8.04B | $24.87B |
Sector | Health | Financials |
52-Week High | $339.75 | $120.16 |
52-Week Low | $241.71 | $86.19 |
Enterprise Value | $7.85B | $21.58B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
T. Rowe Price (TROW) trades at $113.65, down 4.13% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported June 2026 AUM of $1.89 trillion (PRNewsWire, 2026-07-13), showing steady growth. Recent earnings beat expectations in Q1 2026 with EPS of $2.52 versus $2.33 forecast. Valuation ratios remain attractive with a P/E of 12.19 and ROE of 19.31%, supported by strong cash flow trends.
TROW presents a mixed outlook: analyst consensus is cautious with 63% hold ratings and a $109.17 price target below current levels, but fundamentals like rising net cash flow to $909M in 2026 and a 28.28% net margin offer stability. Key risks include equity outflows and market volatility, while the dividend yield near 4.9% (Investors Business Daily, 2026-06-10) provides income appeal. Upside depends on sustained AUM growth and execution against competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
